new warnings not to use high doses of IV ondansetron due to the risk of QT prolongation

Please see updated FDA information (December 4, 2012) regarding the removal of 32 mg IV ondansetron products from the market.

You'll hear new warnings not to use high doses of IV ondansetron due to the risk of QT prolongation.

The max recommended single IV dose is now 16 mg instead of 32 mg.

This is similar to recent concerns about QT prolongation with higher doses of IV dolasetron (Anzemet). IV dolasetron is no longer approved for use for chemo-induced nausea and vomiting.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote